CN115611854B - 一种制备那拉曲坦及其衍生物的新方法 - Google Patents
一种制备那拉曲坦及其衍生物的新方法 Download PDFInfo
- Publication number
- CN115611854B CN115611854B CN202110799182.3A CN202110799182A CN115611854B CN 115611854 B CN115611854 B CN 115611854B CN 202110799182 A CN202110799182 A CN 202110799182A CN 115611854 B CN115611854 B CN 115611854B
- Authority
- CN
- China
- Prior art keywords
- compound
- indole
- boc
- naratriptan
- vinyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960005254 naratriptan Drugs 0.000 title claims abstract description 21
- 238000000034 method Methods 0.000 title claims abstract description 17
- UNHGSHHVDNGCFN-UHFFFAOYSA-N naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 title claims abstract 9
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 17
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 17
- 150000001875 compounds Chemical class 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 16
- LLLQQESOZZJGQC-UHFFFAOYSA-N tert-butyl 5-ethenylindole-1-carboxylate Chemical compound C=CC1=CC=C2N(C(=O)OC(C)(C)C)C=CC2=C1 LLLQQESOZZJGQC-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229940079593 drug Drugs 0.000 claims abstract description 9
- HUUPVABNAQUEJW-UHFFFAOYSA-N 1-methylpiperidin-4-one Chemical compound CN1CCC(=O)CC1 HUUPVABNAQUEJW-UHFFFAOYSA-N 0.000 claims abstract description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000001257 hydrogen Substances 0.000 claims abstract description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 8
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 claims abstract description 6
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 claims abstract description 6
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 claims abstract description 6
- 239000003513 alkali Substances 0.000 claims abstract description 5
- 238000007112 amidation reaction Methods 0.000 claims abstract description 3
- 239000012300 argon atmosphere Substances 0.000 claims abstract description 3
- 239000012298 atmosphere Substances 0.000 claims abstract description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 3
- 238000005984 hydrogenation reaction Methods 0.000 claims abstract description 3
- 238000007342 radical addition reaction Methods 0.000 claims abstract description 3
- 150000003254 radicals Chemical class 0.000 claims abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 48
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 27
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 16
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 14
- 230000035484 reaction time Effects 0.000 claims description 11
- TXNLQUKVUJITMX-UHFFFAOYSA-N 4-tert-butyl-2-(4-tert-butylpyridin-2-yl)pyridine Chemical compound CC(C)(C)C1=CC=NC(C=2N=CC=C(C=2)C(C)(C)C)=C1 TXNLQUKVUJITMX-UHFFFAOYSA-N 0.000 claims description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 7
- WLHCBQAPPJAULW-UHFFFAOYSA-N 4-methylbenzenethiol Chemical compound CC1=CC=C(S)C=C1 WLHCBQAPPJAULW-UHFFFAOYSA-N 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 5
- AZWSUNYFIOQIAH-UHFFFAOYSA-N n,n-dimethyl-2-[3-(1-methylpiperidin-4-yl)-1h-indol-5-yl]ethanesulfonamide Chemical compound C12=CC(CCS(=O)(=O)N(C)C)=CC=C2NC=C1C1CCN(C)CC1 AZWSUNYFIOQIAH-UHFFFAOYSA-N 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 abstract description 21
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 abstract description 18
- 239000002904 solvent Substances 0.000 abstract description 12
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 abstract description 9
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 abstract description 9
- 239000002253 acid Substances 0.000 abstract description 8
- 239000011941 photocatalyst Substances 0.000 abstract description 8
- -1 amine sulfonyl chloride Chemical class 0.000 abstract description 7
- 239000003638 chemical reducing agent Substances 0.000 abstract description 6
- 238000010438 heat treatment Methods 0.000 abstract description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- AMKVXSZCKVJAGH-UHFFFAOYSA-N naratriptan Chemical compound C12=CC(CCS(=O)(=O)NC)=CC=C2NC=C1C1CCN(C)CC1 AMKVXSZCKVJAGH-UHFFFAOYSA-N 0.000 description 13
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000004440 column chromatography Methods 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- 239000003960 organic solvent Substances 0.000 description 8
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 8
- 238000002844 melting Methods 0.000 description 7
- 230000008018 melting Effects 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- 239000003208 petroleum Substances 0.000 description 6
- PPXMUBLAPJLGNE-UHFFFAOYSA-N 2-(1h-indol-5-yl)-n-methylethanesulfonamide Chemical compound CNS(=O)(=O)CCC1=CC=C2NC=CC2=C1 PPXMUBLAPJLGNE-UHFFFAOYSA-N 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 238000000967 suction filtration Methods 0.000 description 5
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
- WIIDGNMSVDHSJW-UHFFFAOYSA-N 2-(1h-indol-5-yl)-n,n-dimethylethanesulfonamide Chemical compound CN(C)S(=O)(=O)CCC1=CC=C2NC=CC2=C1 WIIDGNMSVDHSJW-UHFFFAOYSA-N 0.000 description 4
- WKSDBJDINSQBCC-UHFFFAOYSA-N CC(C)(C)OC(N1C2=CC=C(CCS(NC)(=O)=O)C=C2C=C1)=O Chemical compound CC(C)(C)OC(N1C2=CC=C(CCS(NC)(=O)=O)C=C2C=C1)=O WKSDBJDINSQBCC-UHFFFAOYSA-N 0.000 description 4
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- BXRFQSNOROATLV-UHFFFAOYSA-N 4-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=C(C=O)C=C1 BXRFQSNOROATLV-UHFFFAOYSA-N 0.000 description 3
- QUCRCMAGYMXUKA-UHFFFAOYSA-N CC(C)(C)OC(N1C2=CC=C(CCS(N(C)C)(=O)=O)C=C2C=C1)=O Chemical compound CC(C)(C)OC(N1C2=CC=C(CCS(N(C)C)(=O)=O)C=C2C=C1)=O QUCRCMAGYMXUKA-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 230000006837 decompression Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- PEKAELDGTPPFOJ-UHFFFAOYSA-N 2-(4-methoxyphenyl)benzenethiol Chemical compound C1=CC(OC)=CC=C1C1=CC=CC=C1S PEKAELDGTPPFOJ-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229940124433 antimigraine drug Drugs 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- QAHVHSLSRLSVGS-UHFFFAOYSA-N sulfamoyl chloride Chemical compound NS(Cl)(=O)=O QAHVHSLSRLSVGS-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- DLMYXFNCIVZCRA-UHFFFAOYSA-N 2-(4-methylphenyl)benzenethiol Chemical compound C1=CC(C)=CC=C1C1=CC=CC=C1S DLMYXFNCIVZCRA-UHFFFAOYSA-N 0.000 description 1
- ROBIGIWSSGFPBO-UHFFFAOYSA-N 2-(4-nitrophenyl)benzenethiol Chemical compound C1=CC([N+](=O)[O-])=CC=C1C1=CC=CC=C1S ROBIGIWSSGFPBO-UHFFFAOYSA-N 0.000 description 1
- VQGHOUODWALEFC-UHFFFAOYSA-N 2-phenylpyridine Chemical compound C1=CC=CC=C1C1=CC=CC=N1 VQGHOUODWALEFC-UHFFFAOYSA-N 0.000 description 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- NSGDYZCDUPSTQT-UHFFFAOYSA-N N-[5-bromo-1-[(4-fluorophenyl)methyl]-4-methyl-2-oxopyridin-3-yl]cycloheptanecarboxamide Chemical compound Cc1c(Br)cn(Cc2ccc(F)cc2)c(=O)c1NC(=O)C1CCCCCC1 NSGDYZCDUPSTQT-UHFFFAOYSA-N 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000002460 anti-migrenic effect Effects 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Indole Compounds (AREA)
Abstract
本发明提供一种以商业可得的5‑乙烯基‑N‑Boc吲哚为原料制备药物naratriptan及其衍生物的方法,如路线1所示:5‑乙烯基‑N‑Boc吲哚A在一定溶剂中,氩气氛围,还原剂,硫酚和光催化剂共同作用,蓝光源照射下与脂肪胺基磺酰氯B发生自由基加成和硫酚协调氢原子转移的氢化磺酰胺化反应制得5‑(2‑脂肪胺基磺酰乙基)‑N‑Boc‑吲哚C。化合物C在一定溶剂中,酸,一定室温条件下,脱Boc制得5‑(2‑脂肪胺基磺酰乙基)吲哚D。化合物D在一定溶剂中,碱和加热条件下,与N‑甲基‑4‑哌啶酮缩合制得3‑(1,2,3,6‑四氢‑1‑甲基吡啶‑4‑烯基)‑5‑(2‑脂肪胺基磺酰基乙基)吲哚E。化合物E在一定溶剂中,氢气氛围,钯碳和一定温度条件下,制得药物naratriptan及其衍生物F。式中R1‑R2指代内容详见说明书。路线以商业可得的5‑乙烯基‑N‑Boc吲哚为起始原料,4步,32%的总收率,实现了药物naratriptan的合成。
Description
技术领域
本发明属于精细化学品技术领域,该方法可用于抗偏头痛药物那拉曲坦(naratriptan)及其衍生物的高效制备。
背景技术
偏头痛是一种慢性的致衰弱疾病,严重影响病人的生活质量。葛兰素威康公司开发的第二代抗偏头痛药物naratriptan是目前抗偏头痛药物中作用最强最持久的药物。其结构中的5-(2-甲基胺基磺酰基乙基)吲哚是制备药物naratriptan的关键原料,传统的合成路线是以4-硝基苯甲醛为起始原料,经过总收率低于10%,繁琐的步骤或以5-甲醛-N-Boc吲哚为起始原料,在苛刻的条件(-78℃)下与N-甲基甲磺酰胺负离子反应,再进一步还原制得,而这些方法都具有一定的局限性(Organic Process Research&Development,2009,13,468-470;Heterocycles,2003,60,2441-2455)。因此,我们开发一种以商业可得的5-乙烯基-N-Boc吲哚为起始原料,反应条件温和,高效的制备药物naratriptan及其衍生物的方法。该方法以4步,32%的总收率,实现了药物naratriptan的合成。
发明内容
本发明的目的是提供一种以商业可得的5-乙烯基-N-Boc吲哚为原料制备药物naratriptan及其衍生物的方法。该方法操作简单,合成路线简介,反应条件温和,收率高。
路线1
式中:R1-R2各自独立地选自H、C1-C6的烷基、C1-C6的烷氧基、C1-C6的羟烷基、C6-C10的芳基、C3-C10的杂环。
本发明的一种制备药物naratriptan及其衍生物的方法如路线1所示:5-乙烯基-N-Boc吲哚A在一定溶剂中,氩气氛围,还原剂,硫酚和光催化剂共同作用,蓝光源照射下与脂肪胺基磺酰氯B发生自由基加成和硫酚协调氢原子转移的氢化磺酰胺化反应制得5-(2-脂肪胺基磺酰乙基)-N-Boc-吲哚C。化合物C在一定溶剂中,酸,一定室温条件下,脱Boc制得5-(2-脂肪胺基磺酰乙基)吲哚D。化合物D在一定溶剂中,碱和加热条件下,与N-甲基-4-哌啶酮缩合制得3-(1,2,3,6-四氢-1-甲基吡啶-4-烯基)-5-(2-脂肪胺基磺酰基乙基)吲哚E。化合物E在一定溶剂中,氢气氛围,钯碳和一定温度条件下,制得药物naratriptan及其衍生物F。
本路线步骤I中5-乙烯基-N-Boc吲哚(A)、光催化剂、硫酚、脂肪胺基磺酰氯(B)、还原剂的摩尔比是1∶0.002-0.2∶0.1-1∶1-5∶1-5。
步骤I中的温度范围为-30-80℃,最佳的反应温度为20-50℃。
步骤I中的反应时间为0.5-48小时,最佳反应时间为1-36小时。
步骤I中所使用的还原剂为N,N-二异丙基乙胺或汉斯酯,最佳还原剂为汉斯酯。
步骤I中所使用的硫酚为4-甲氧基苯硫酚、苯硫酚、4-甲氧基苯硫酚或4-硝基苯硫酚,最佳为4-甲基苯硫酚。
步骤I中所使用的有机溶剂为乙醇、甲醇、环己烷、正己烷、正戊烷、正庚烷、石油醚、乙醚、四氢呋喃、二氯甲烷、三氯甲烷、四氯化碳、1,2-二氯乙烷、乙腈或上述任意两种溶剂的组合,最佳的有机溶剂为乙腈。
步骤I中不加光催化剂或不加碱或不加还原剂或不光照的条件下,均不能发生。
步骤I中光催化剂为[Ir{dF(CF3)ppy}2(dtbbpy)]PF6,[Ir(dtbbpy)(ppy)2]PF6,Eosin Y,Ru(bpy)3(PF6)2,Ir(ppy)3或Mes-Acr+。
本路线步骤II中5-(2-脂肪胺基磺酰乙基)-N-Boc-吲哚(C)、酸的摩尔比是1∶1-10。
步骤II中的温度范围为-30-80℃,最佳的反应温度为0℃。
步骤II中的反应时间为3-24小时,最佳反应时间为6-10小时。
步骤II中所使用的酸为乙酸,三氟乙酸或盐酸。最佳酸为三氟乙酸。
步骤II中所使用的有机溶剂为乙醇、甲醇、环己烷、正己烷、正戊烷、正庚烷、石油醚、乙醚、四氢呋喃、二氯甲烷、三氯甲烷、四氯化碳、1,2-二氯乙烷、乙腈或上述任意两种溶剂的组合,最佳的有机溶剂为二氯甲烷。
本路线步骤III中5-(2-脂肪胺基磺酰乙基)吲哚(D)、碱、N-甲基-4-哌啶酮的摩尔比是1∶1-5∶1-5。
步骤III中的温度范围为-30-120℃,最佳的反应温度为80℃。
步骤III中的反应时间为3-36小时,最佳反应时间为12-24小时。
步骤III中所使用的碱为碳酸氢钠,氢氧化钠,碳酸钠,碳酸钾或碳酸铯,最佳碱为碳酸钾。
步骤III中所使用的有机溶剂为乙醇、甲醇、环己烷、正己烷、正戊烷、正庚烷、石油醚、乙醚、四氢呋喃、二氯甲烷、三氯甲烷、四氯化碳、1,2-二氯乙烷、乙腈或上述任意两种溶剂的组合,最佳的有机溶剂为乙醇。
本路线步骤IV中3-(1,2,3,6-四氢-1-甲基吡啶-4-烯基)-5-(2-脂肪胺基磺酰基乙基)吲哚(E)、钯碳、酸的摩尔比是1∶0.1-1∶1-5。
步骤IV中的温度范围为-30-120℃,最佳的反应温度为24℃。
步骤IV中的氢气压强为1-100atm,最佳的压强为10atm。
步骤IV中的反应时间为1-12小时,最佳反应时间为4-6小时。
步骤IV中所使用的酸为乙酸,三氟乙酸或盐酸,最佳酸为乙酸。
步骤IV中所使用的有机溶剂为乙醇、甲醇、环己烷、正己烷、正戊烷、正庚烷、石油醚、乙醚、四氢呋喃、二氯甲烷、三氯甲烷、四氯化碳、1,2-二氯乙烷、乙腈或上述任意两种溶剂的组合,最佳的有机溶剂为甲醇。
与现有技术相比,本发明具有的突出的实质性特点和显著进步如下:该方法操作简单,合成路线简洁,反应条件温和,收率高。路线以商业可得的5-乙烯基-N-Boc吲哚为起始原料,4步,32%的总收率,实现了药物naratriptan的合成。
具体实施方式
实施例1:5-(2-脂肪胺基磺酰乙基)-N-Boc-吲哚C的合成
将1.0当量的5-乙烯基-N-Boc吲哚A与1.0-5.0当量的脂肪胺基磺酰氯、0.2-2.0mmol%的光催化剂[Ir(dF(CF3)ppy)2(dtbbpy)]PF6、1.0-5.0当量的汉斯酯、0.2-1.0当量4-甲基苯硫酚、2-5mL乙腈加入10mL Schlenk管,通过双排管,氩气抽放气3-5次,在15W的465~475nm蓝光照射下反应3~12小时,加入饱和NaCl溶液和二氯甲烷萃取,有机层干燥,真空减压脱溶,柱层析得到5-(2-脂肪胺基磺酰乙基)-N-Boc-吲哚C。
5-(2-甲基胺基磺酰基乙基)-N-Boc吲哚(C1)的合成(路线2)
路线2
将A(73.0mg,0.3mmol,1.0equiv)和脂肪胺基磺酰氯B1(77.8mg,0.60mmol,2.0equiv)、汉斯脂(152.0mg,0.60mmol,2.0equiv)、4-甲基苯硫酚(7.5mg,0.06mmol,20mol%)、光催化剂[Ir(dF(CF3)ppy)2(dtbbpy)]PF6(6.7mg,0.06mmol,2.0mol%)和2mL乙腈加入10mL Schlenk管,通过双排管,氩气抽放气3-5次,在15W的465-475nm蓝光照射,25℃下反应3小时,加入20mL水,分别用10mL二氯甲烷萃取三次。有机层用无水硫酸钠干燥。抽滤后,真空减压脱溶,通过柱层析(石油醚/乙酸乙酯=5∶1,v/v)得到目标产物C1(1.5g,4.44mmol,74%),产物为无色油状物。1H NMR(400MHz,CDCl3)δ8.01(d,J=8.1Hz,1H,Ar-H),7.52(d,J=3.5Hz,1H,Ar-H),7.34(s,1H,Ar-H),7.09(dd,J=8.5,1.4Hz,1H,Ar-H),6.44(d,J=3.7Hz,1H,Ar-H),4.07-3.98(m,1H,NH),3.26(dd,J=9.8,5.6Hz,2H,CH2),3.13(dd,J=9.8,5.8Hz,2H,CH2),2.61(d,J=5.3Hz,3H,N-CH3),1.59(s,9H,CH3).13C NMR(100MHz,CDCl3)δ149.6,134.2,132.1,131.0,126.6,124.5,120.5,115.5,107.0,83.9,52.6,29.9,29.3,28.2.HRMS(ESI):Cacld for C16H23N2O4S[M+H]+339.1373,found 339.1375.
5-(2-(N,N-二甲基胺基磺酰基)乙基)-N-Boc吲哚(C2)的合成(路线3)
路线3
将A(73.0mg,0.3mmol,1.0equiv)和脂肪胺基磺酰氯B2(0.60mmol,2.0equiv)、汉斯脂(152.0mg,0.60mmol,2.0equiv)、4-甲基苯硫酚(7.5mg,0.06mmol,20mol%)、光催化剂[Ir(dF(CF3)ppy)2(dtbbpy)]PF6(6.7mg,0.06mmol,2.0mol%)和2mL乙腈加入10mL Schlenk管,通过双排管,氩气抽放气3-5次,在15W的465-475nm蓝光照射下反应3小时,加入20mL水,分别用10mL二氯甲烷萃取三次。有机层用无水硫酸钠干燥。抽滤后,真空减压脱溶,通过柱层析(石油醚/乙酸乙酯=5∶1,v/v)得到目标产物C2(1.8g,5.22mmol,87%),产物为棕色固体,熔点73-74℃。1H NMR(400MHz,CDCl3)δ8.08(d,J=8.2Hz,1H,Ar-H),7.59(d,J=3.6Hz,1H,Ar-H),7.40(d,J=1.4Hz,1H,Ar-H),7.16(dd,J=8.5,1.7Hz,1H,Ar-H),6.52(d,J=3.7Hz,1H,Ar-H),3.21(m,4H,CH2),2.88(s,6H,N-CH3),1.67(s,9H,CH3).13C NMR(100MHz,CDCl3)δ149.7,132.4,131.0,126.5,124.5,120.5,115.5,107.0,83.8,50.2,37.5,29.3,28.2.HRMS(ESI):Cacld for C17H25N2O4S[M+H]+353.1530,found 353.1533.
实施例2:5-(2-脂肪胺基磺酰乙基)吲哚D的合成
将1.0当量的化合物C与1-5mL的三氟乙酸,4-20mL二氯甲烷加入圆底烧瓶中,在0℃条件下反应6~10小时,使用5M碳酸氢钠调节PH至8~9,用二氯甲烷萃取(20mL×3),有机层用无水硫酸钠干燥。抽滤后,真空减压脱溶得到目标产物D。
5-(2-甲基胺基磺酰基乙基)吲哚(D1)的合成(路线4)
路线4
将化合物C1(169.2mg,0.5mmol,1.0equiv)与3mL的三氟乙酸,12mL二氯甲烷加入圆底烧瓶中,在0℃条件下反应10小时,使用5M碳酸氢钠调节PH至8~9,用二氯甲烷萃取(20mL×3),有机层用无水硫酸钠干燥。抽滤后,真空减压脱溶得到目标产物D1(106.0mg,89%),产物为白色固体,熔点119-120℃。1H NMR(400MHz,DMSO-d6)δ11.01(s,1H,NH),7.42(s,1H,Ar-H),7.31(dd,J=7.2,5.5Hz,2H,Ar-H),7.00-6.93(m,2H,Ar-H+NH),6.36(s,1H,Ar-H),3.33-3.21(m,2H,CH2),3.05-2.92(m,2H,CH2),2.61(d,J=4.9Hz,3H,N-CH3).13C NMR(100MHz,DMSO-d6)δ140.0,133.9,133.1,130.8,126.9,124.6,116.6,105.9,56.6,34.6,33.9.HRMS(ESI):Cacld for C11H15N2O2S[M+H]+239.0849,found 239.0853.
5-(2-(N,N-二甲基胺基磺酰基)乙基)吲哚(D2)的合成(路线5)
路线5
将化合物C2(176.2mg,0.5mmol,1.0equiv)与3mL的三氟乙酸,12mL二氯甲烷加入圆底烧瓶中,在0℃条件下反应10小时,使用5M碳酸氢钠调节PH至8~9,用二氯甲烷萃取(20mL×3),有机层用无水硫酸钠干燥。抽滤后,真空减压脱溶得到目标产物D2(119.8mg,95%),产物为白色固体,熔点119-120℃。1H NMR(400MHz,CDCl3)δ8.23(s,1H,Ar-H),7.47(s,1H,Ar-H),7.35(d,J=8.3Hz,1H,Ar-H),7.21(t,J=2.8Hz,1H,Ar-H),7.03(dd,J=8.3,1.5Hz,1H,Ar-H),6.59-6.46(m,1H,Ar-H),3.24-3.18(m,4H,CH2),2.88(s,6H,N-CH3).13CNMR(100MHz,CDCl3)δ134.8,129.4,128.3,124.9,122.5,120.1,111.4,102.3,50.5,37.5,29.4.HRMS(ESI):Cacld for C12H17N2O2S[M+H]+253.1005,found 253.1006.
实施例3:3-(1,2,3,6-四氢-1-甲基吡啶-4-烯基)-5-(2-脂肪胺基磺酰基乙基)吲哚E的合成
将1.0当量的化合物D与1-5当量的碳酸钾,1-5当量的N-甲基-4-哌啶酮,4-20mL乙醇加入圆底烧瓶中,在80℃条件下反应12~24小时,加入饱和NaCl溶液和乙酸乙酯萃取,有机层干燥,真空减压脱溶,柱层析得到3-(1,2,3,6-四氢-1-甲基吡啶-4-烯基)-5-(2-脂肪胺基磺酰基乙基)吲哚E。
3-(1,2,3,6-四氢-1-甲基吡啶-4-烯基)-5-(2-甲基胺基磺酰基乙基)吲哚(E1)的合成(路线6)
路线6
将化合物D1(119.2mg,0.5mmol,1.0equiv)与碳酸钾(138.2mg,1mmol,2.0equiv),N-甲基-4-哌啶酮(62.2mg,0.55mmol,1.1equiv),10mL乙醇加入圆底烧瓶中,在80℃条件下反应12小时,加入饱和NaCl溶液40mL和乙酸乙酯40mL萃取,有机层干燥,真空减压脱溶,柱层析得到化合物E1(106.7mg,64%),产物为白色固体,熔点215-216℃。1H NMR(400MHz,DMSO-d6)δ11.11(s,1H,NH),7.70(s,1H,Ar-H),7.35(d,J=1.2Hz,1H,Ar-H),7.31(d,J=8.3Hz,1H,Ar-H),7.01(d,J=8.5Hz,1H,Ar-H),6.99(s,1H,NH),6.15(s,1H,Ar-H),3.35-3.30(m,2H,N-CH2),3.32-3.27(m,2H,N-CH2),3.05(t,J=8.0Hz,2H,CH2),3.02(t,J=8.0Hz,2H,CH2),2.62(s,3H,SO2N-CH3),2.56(t,J=5.3Hz,2H,CH-CH2),2.28(s,3H,N-CH3).13C NMR(100MHz,DMSO-d6)δ136.3,129.7,129.7,125.4,123.6,122.5,120.1,118.1,116.2,112.2,55.2,52.5,52.0,46.3,30.1,29.2,29.1,29.0.HRMS(ESI):Cacld forC17H24N3O2S[M+H]+334.1584,found 334.1588.
3-(1,2,3,6-四氢-1-甲基吡啶-4-烯基)-5-(2-(N,N-二甲基胺基磺酰基)乙基)吲哚(E2)的合成(路线7)
路线7
将化合物D2(126.2mg,0.5mmol,1.0equiv)与碳酸钾(138.2mg,1mmol,2.0equiv),N-甲基-4-哌啶酮(62.2mg,0.55mmol,1.1equiv),10mL乙醇加入圆底烧瓶中,在80℃条件下反应12小时,加入饱和NaCl溶液40mL和乙酸乙酯40mL萃取,有机层干燥,真空减压脱溶,柱层析得到化合物E2(114.7mg,66%),产物为白色固体,熔点239-240℃。1H NMR(400MHz,DMSO-d6)δ11.10(s,1H,NH),7.72(s,1H,Ar-H),7.44-7.21(m,2H,Ar-H+CH),7.04(d,J=7.8Hz,1H,Ar-H),6.16(s,1H,Ar-H),3.34-3.23(m,4H,CH2),3.08-3.04(m,4H,CH2),2.79(s,6H,SO2N-CH3),2.57(t,J=3.5Hz,2H,CH2),2.29(s,3H,N-CH3).13C NMR(100MHz,DMSO-d6)δ129.2,129.0,124.9,123.1,122.0,119.8,117.6,115.7,111.7,54.7,52.0,48.6,45.7,37.1,28.9,28.5.HRMS(ESI):Cacld for C18H26N3O2S[M+H]+348.1740,found 348.1741.
实施例4:目标产物F的合成
将1.0当量的化合物E与0.1-1当量的钯碳,1-5当量的乙酸,4-20mL甲醇加入圆底烧瓶中,在在1-100atm氢气压强和24℃条件下反应4~6小时,抽滤,减压脱溶,柱层析得到F。
3-(1-甲基-4-哌啶基)-5-(2-甲基胺基磺酰基乙基)吲哚(F1,那拉曲坦)的合成(路线8)
路线8
将化合物E1(333.5mg,1mmol,1.0equiv)与钯碳(10%,106mg,0.1mmol,0.1equiv),乙酸(300.3mg,5mmol,5.0equiv),20mL甲醇加入圆底烧瓶中,在在10atm氢气压强和24℃条件下反应6小时,抽滤,真空减压脱溶,柱层析得到化合物F1(255mg,76%),产物为白色固体,熔点231-232℃1H NMR(400MHz,DMSO-d6)δ:1.66(m,2H),1.89(m,2H),2.05(m,2H),2.20(m,2H),2.60(m,2H),2.68(m,1H),2.85(m,2H),2.99(m,2H),3.28(m,2H),6.95(m,2H),7.05(d,1H),7.25(d,1H),7.43(s,1H),10.71(s,1H).HRMS(ESI):Cacld forC17H25N3O2S[M+H]+335.1667,found 335.1670.
3-(1-甲基-4-哌啶基)-5-(2-(N,N-二甲基胺基磺酰基)乙基)吲哚(F2)的合成(路线9)
路线9
将化合物E2(347.5mg,1mmol,1.0equiv)与钯碳(10%,106mg,0.1mmol,0.1equiv),乙酸(300.3mg,5mmol,5.0equiv),20mL甲醇加入圆底烧瓶中,在10atm氢气压强和24℃条件下反应6小时,抽滤,真空减压脱溶,柱层析得到化合物F2(293.6mg,84%),产物为白色固体,熔点231-232℃。1H NMR(400MHz,DMSO-d6)δ10.83(s,1H,NH),7.56(s,1H,Ar-H),7.27(d,J=8.3Hz,1H,Ar-H),7.08(d,J=2.0Hz,1H,Ar-H),7.00(d,J=8.3Hz,1H,Ar-H),3.36-3.31(m,2H,CH2),3.17-3.14(m,2H,CH2),3.06-3.04(m,2H),2.90-2.85(m,2H),2.79(s,6H,N-CH3),2.61-2.58(m,2H),2.42-2.44(m,1H),2.01-1.95(m,2H),1.90(s,3H,N-CH3).13C NMR(100MHz,DMSO-d6)δ135.9,128.4,126.8,122.24,121.7,118.7,112.0,55.2,49.0,37.6,32.0,31.4,29.3.HRMS(ESI):Cacld for C18H28N3O2S[M+H]+350.1897,found350.1895.
以上详细描述了本发明的优选实施方式,但是,本发明并不限于此。在本发明的技术构思范围内,可以对本发明的技术方案进行多种简单变型,包括各个技术特征以任何其它的合适方式进行组合,这些简单变型和组合同样应当视为本发明所公开的内容,均属于本发明的保护范围。
Claims (3)
1.一种以5-乙烯基-N-Boc吲哚为原料制备药物naratriptan及其衍生物的方法,其特征在于5-乙烯基-N-Boc吲哚A在乙腈中,氩气氛围,汉斯酯、4-甲基苯硫酚和[Ir(dF(CF3)ppy)2(dtbbpy)]PF6共同作用,蓝光源照射下与化合物B发生自由基加成和4-甲基苯硫酚协调氢原子转移的氢化磺酰胺化反应制得化合物C;化合物C在二氯甲烷和三氟乙酸中,0℃条件下,脱Boc制得化合物D;化合物D在乙醇中,碳酸钾为碱,80℃条件下,与N-甲基-4-哌啶酮缩合制得化合物E;化合物E在甲醇和乙酸中,氢气氛围,钯碳和24℃条件下,制得药物naratriptan及其衍生物F:
式中:R1=H,R2=CH3;或R1=R2=CH3;
步骤I中5-乙烯基-N-Boc吲哚A、[Ir(dF(CF3)ppy)2(dtbbpy)]PF6、4-甲基苯硫酚、化合物B、汉斯酯的摩尔比是1∶0.002-0.2∶0.1-1∶1-5∶1-5;
步骤II中化合物C、三氟乙酸的摩尔比是1∶1-10;
步骤II中的反应时间为3-24小时;
步骤III中化合物D、碳酸钾、N-甲基-4-哌啶酮的摩尔比是1∶1-5∶1-5;
步骤III中的反应时间为3-36小时;
步骤IV中化合物E、钯碳、乙酸的摩尔比是1∶0.1-1∶1-5;
步骤IV中的氢气压强为1-100atm;
步骤IV中的反应时间为1-12小时。
2.权利要求1所述的以5-乙烯基-N-Boc吲哚为原料制备药物naratriptan及其衍生物的方法,其特征在于通过该方法以4步,32%的总收率,实现了药物naratriptan的合成。
3.权利要求1所述的以5-乙烯基-N-Boc吲哚为原料制备药物naratriptan及其衍生物的方法,其特征在于通过该方法实现3-(1-甲基-4-哌啶基)-5-(2-(N,N-二甲基胺基磺酰基)乙基)吲哚的合成。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110799182.3A CN115611854B (zh) | 2021-07-15 | 2021-07-15 | 一种制备那拉曲坦及其衍生物的新方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110799182.3A CN115611854B (zh) | 2021-07-15 | 2021-07-15 | 一种制备那拉曲坦及其衍生物的新方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115611854A CN115611854A (zh) | 2023-01-17 |
CN115611854B true CN115611854B (zh) | 2024-03-26 |
Family
ID=84855762
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110799182.3A Active CN115611854B (zh) | 2021-07-15 | 2021-07-15 | 一种制备那拉曲坦及其衍生物的新方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115611854B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1789262A (zh) * | 2004-12-16 | 2006-06-21 | 上海美通生物科技有限公司 | Naratriptan制备的改进法 |
WO2008056378A2 (en) * | 2006-11-09 | 2008-05-15 | Natco Pharma Limited | Novel process for the preparation of naratriptan hydrochloride |
CN101676283A (zh) * | 2008-09-17 | 2010-03-24 | 北京德众万全药物技术开发有限公司 | 一种那拉曲坦的制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ597620A (en) * | 2009-08-20 | 2013-08-30 | Cipla Ltd | A process for the synthesis of naratriptan |
-
2021
- 2021-07-15 CN CN202110799182.3A patent/CN115611854B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1789262A (zh) * | 2004-12-16 | 2006-06-21 | 上海美通生物科技有限公司 | Naratriptan制备的改进法 |
WO2008056378A2 (en) * | 2006-11-09 | 2008-05-15 | Natco Pharma Limited | Novel process for the preparation of naratriptan hydrochloride |
CN101676283A (zh) * | 2008-09-17 | 2010-03-24 | 北京德众万全药物技术开发有限公司 | 一种那拉曲坦的制备方法 |
Non-Patent Citations (1)
Title |
---|
"Generation and precise control of sulfonyl radicals: visible-light-activated redox-neutral formation of sulfonates and sulfonamides";Zhang Mingjun等;Org. Chem. Front.;第8卷;第961-967页 * |
Also Published As
Publication number | Publication date |
---|---|
CN115611854A (zh) | 2023-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1471920B1 (en) | Process for preparing water-soluble phosphonooxymethyl derivatives of alcohol and phenol | |
KR20120139763A (ko) | 랄테그라비어 염 및 이의 결정형 | |
NO172577B (no) | Fremgangsmaate og mellomprodukter ved fremstilling av substituerte indolinonderivater | |
CN115611854B (zh) | 一种制备那拉曲坦及其衍生物的新方法 | |
WO2013107428A1 (zh) | 7-位取代的汉防己乙素衍生物、及其制备方法和应用 | |
US5728709A (en) | Alkyl and aralkyl-substituted pyrrolocarbazole derivatives that stimulate platelet production | |
CN111848445A (zh) | 一种用于生产酰氧基烯胺的改进方法 | |
KR100559019B1 (ko) | 헤테로사이클릭 인덴 유사체의 제조 방법 | |
CN115215814A (zh) | 异恶唑烷类化合物的合成方法 | |
CN112645863B (zh) | 二吡咯甲烯-1-酮类化合物及其制备方法 | |
CN114790212B (zh) | 恶嗪并异吲哚和恶嗪并异喹啉化合物及其制备方法 | |
CN101279948B (zh) | 4,6-二氯-5-(2-甲氧基苯氧基)-2,2'-二嘧啶的合成方法 | |
JPH04330070A (ja) | ラブダン類およびその製造方法 | |
CN107365264B (zh) | 一种磺酰胺类化合物的制备方法 | |
WO2024000877A1 (zh) | 一种尼古丁的制备方法 | |
Sashida et al. | Reactions of 1-benzoselenopyrylium salts with nucleophiles: Formation of functionalised selenochromenes1 | |
CN111377867B (zh) | 一种合成2-(1-烷基-1h-吡唑-4-基)吗啉的中间体及其制备方法和应用 | |
TWI843678B (zh) | 用於製備2-(2,6-二氯苯基)-1-[(1s,3r)-3-(羥甲基)-5-(3-羥基-3-甲基丁基)-1-甲基-3,4-二氫異喹啉-2(1h)-基]乙烯酮之方法及中間物 | |
JPS59137478A (ja) | メチル−2−テトラデシルグリシデ−トの製法 | |
CN108191728B (zh) | 二硫代甲酸衍生物及其制备方法 | |
KR20060114985A (ko) | 2-(2-아미노에틸)-1-메틸피롤리딘의 제조방법 | |
CN117105802A (zh) | 一种氨基醇类衍生物的制备方法 | |
JP6235043B2 (ja) | N−(4−ニトロ−2−スルファモイル−フェニル)−マロンアミド酸メチルエステルおよびn−(4−アミノ−2−スルファモイル−フェニル)−マロンアミド酸メチルエステルの製造のための新規な製法 | |
CN100358866C (zh) | 含对强碱不稳定取代基的n-乙烯基取代吡咯的制备方法 | |
CN118026955A (zh) | 一种光学活性马来酸噻吗洛尔的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |